Top

Nuclear Medicine and Molecular Imaging

Published in:

01-03-2017 | Original Article

The Role of F-18 FDG PET/CT in Intrahepatic Cholangiocarcinoma

Authors: Yeongjoo Lee, Ie Ryung Yoo, Sun Ha Boo, Hyoungwoo Kim, Hye Lim Park, Joo Hyun O

Published in: Nuclear Medicine and Molecular Imaging | Issue 1/2017

Abstract

Purpose

The aim of this study was to evaluate the diagnostic and prognostic role of metabolic parameters of FDG PET/CT in patients with intrahepatic cholangiocarcinoma (ICC).

Methods

From December 2008 to December 2013, 76 FDG PET/CT scans performed for initial staging of ICC in a single institution (57 male and 19 female; mean age 68 ± 9 years) were retrospectively reviewed. Patients with history of other known malignancy were excluded. Detection rates of regional lymph node and distant metastasis by FDG PET/CT were analyzed in comparison with conventional imaging modalities such as CT or MRI. Metabolic parameters including maximum, peak and mean standardized uptake values (SUVmax, SUVpeak, SUVmean), metabolic tumor volume (MTV), total lesion glycolysis (TLG), glucose corrected SUV (SUVgluc), and glucose corrected TLG (TLGgluc) were measured for the primary tumor. Cut-off values for the metabolic parameters were calculated by ROC curve analysis, and used to dichotomize the patient groups. The overall survival time (OS) was calculated and compared using the Cox proportional hazard regression analysis.

Results

The median duration of follow-up period was 5.4 months (interquartile range: 1.45∼15.45). FDG PET/CT showed higher sensitivity than conventional imaging modalities in detection of regional node involvement (74.5 % vs. 61.8 %, p = 0.013). In six patients, distant metastasis was identified only by FDG PET/CT. The mean SUVmax, SUVpeak, SUVmean, MTV, and TLG for the primary tumor were 8.2 ± 3.1, 6.8 ± 2.5, 4.0 ± 0.8, 192.7 ± 360.5 cm³, and 823.7 ± 1615.4, respectively. Patients with higher (≥7.3, HR: 4.280, p = 0.001), higher SUVpeak (≥6.5, HR: 2.333, p = 0.020), higher SUVmean (≥3.9, HR: 2.799, p = 0.004), higher SUVgluc (≥8.1, HR: 2.648, p = 0.012), and higher TLGgluc (≥431.6, HR: 2.186, p = 0.030) showed significantly shorter survival time. By multivariate study, operability was an independent prognostic factor for longer survival (HR: 4.113, p = 0.005).

Conclusion

FDG PET/CT is an important diagnostic imaging tool in the nodal staging and detection of distant metastasis in ICC patients. Metabolic parameters may have a significant role as prognostic factors in patients with ICC.

Khan SA, Thomas HC, Davidson BR, Taylor-Robinson SD. Cholangiocarcinoma. Lancet. 2005;366(9493):1303–14.CrossRefPubMed

Shaib Y, El-Serag HB. The epidemiology of cholangiocarcinoma. Semin Liver Dis. 2004;24:115–25.CrossRefPubMed

Mouzas IA, Dimoulios P, Vlachonikolis IG, Skordilis P, Zoras O, Kouroumalis E. Increasing incidence of cholangiocarcinoma in Crete 1992-2000. Anticancer Res. 2002;22:3637–41.PubMed

Taylor-Robinson SD, Toledano MB, Arora S, Keegan TJ, Hargreaves S, Beck A, et al. Increase in mortality rates from intrahepatic cholangiocarcinoma in England and Wales 1968-1998. Gut. 2001;48:816–20.CrossRefPubMedPubMedCentral

Shaib YH, Davila JA, McGlynn K, El-Serag HB. Rising incidence of intrahepatic cholangiocarcinoma in the United States: a true increase? J Hepatol. 2004;40:472–7.CrossRefPubMed

Patel T. Increasing incidence and mortality of primary intrahepatic cholangiocarcinoma in the United States. Hepatology. 2001;33:1353–7.CrossRefPubMed

Khan SA, Davidson BR, Goldin RD, Heaton N, Karani J, Pereira SP, et al. Guidelines for the diagnosis and treatment of cholangiocarcinoma: an update. Gut. 2012;61(12):1657–69.CrossRefPubMed

Mavros MN, Economopoulos KP, Alexiou VG, Pawlik TM. Treatment and Prognosis for Patients With Intrahepatic Cholangiocarcinoma: Systematic Review and Meta-analysis. JAMA Surg. 2014;149(6):565–74.CrossRefPubMed

Albazaz R, Patel CN, Chowdhury FU, Scarsbrook AF. Clinical impact of FDG PET-CT on management decisions for patients with primary biliary tumours. Insights Imaging. 2013;4:691–700.CrossRefPubMedPubMedCentral

10.

Kim JY, Kim MH, Lee TY, Hwang CY, Kim JS, Yun SC, et al. Clinical role of 18F-FDG PET-CT in suspected and potentially operable cholangiocarcinoma: a prospective study compared with conventional imaging. Am J Gastroenterol. 2008;103:1145–51.CrossRefPubMed

11.

Park SK, Kim YS, Kim SG, Jang JY, Moon JH, Lee MS, et al. Detection of distant metastasis to skeletal muscle by 18F-FDG-PET in a case of intrahepatic cholangiocarcinoma. Korean J Hepatol. 2010;16:325–8.CrossRefPubMedPubMedCentral

12.

Reinhardt MJ, Strunk H, Gerhardt T, Roedel R, Jaeger U, Bucerius J, et al. Detection of Klatskin’s tumor in extrahepatic bile duct strictures using delayed 18F-FDG PET/CT: preliminary results for 22 patient studies. J Nucl Med. 2005;46:1158–63.PubMed

13.

Annunziata S, Caldarella C, Pizzuto DA, Galiandro F, Sadeghi R, Giovanella L, et al. Diagnostic accuracy of fluorine-18-fluorodeoxyglucose positron emission tomography in the evaluation of the primary tumor in patients with cholangiocarcinoma: a meta-analysis. Biomed Res Int. 2014;2014:247693.CrossRefPubMedPubMedCentral

14.

Fujita N, Asayama Y, Nishie A, Ishigami K, Ushijima Y, Takayama Y et al. Mass-forming intrahepatic cholangiocarcinoma: Enhancement patterns in the arterial phase of dynamic hepatic CT - Correlation with clinicopathological findings. Eur Rad. 2016.

15.

Manfredi R, Barbaro B, Masselli G, Vecchioli A, Marano P. Magnetic resonance imaging of cholangiocarcinoma. Semin Liver Dis. 2004;24:155–64.CrossRefPubMed

16.

Hepatobiliary (NCCN guideline). NCCN clinical practice guidelines in oncology, Version 2. 2015.

17.

Wang Y, Li J, Xia Y, Gong R, Wang K, Yan Z, et al. Prognostic nomogram for intrahepatic cholangiocarcinoma after partial hepatectomy. J Clin Oncol. 2013;31:1188–95.CrossRefPubMed

18.

Ribero D, Pinna AD, Guglielmi A, Ponti A, Nuzzo G, Giulini SM, et al. Surgical Approach for Long-term Survival of Patients With Intrahepatic Cholangiocarcinoma: A Multi-institutional Analysis of 434 Patients. Arch Surg. 2012;147:1107–13.CrossRefPubMed

19.

Sonbare DJ. Influence of surgical margins on outcome in patients with intrahepatic cholangiocarcinoma: a multicenter study by the AFC-IHCC-2009 Study Group. Ann Surg. 2014;259:e36.CrossRefPubMed

20.

de Jong MC, Nathan H, Sotiropoulos GC, Paul A, Alexandrescu S, Marques H, et al. Intrahepatic cholangiocarcinoma: an international multi-institutional analysis of prognostic factors and lymph node assessment. J Clin Oncol. 2011;29:3140–5.CrossRefPubMed

21.

Feydy A, Vilgrain V, Denys A, Sibert A, Belghiti J, Vullierme MP, et al. Helical CT assessment in hilar cholangiocarcinoma: correlation with surgical and pathologic findings. AJR Am J Roentgenol. 1999;172:73–7.CrossRefPubMed

22.

Kluge R, Schmidt F, Caca K, Barthel H, Hesse S, Georgi P, et al. Positron emission tomography with [(18)F]fluoro-2-deoxy-D-glucose for diagnosis and staging of bile duct cancer. Hepatology. 2001;33:1029–35.CrossRefPubMed

23.

Park TG, Yu YD, Park BJ, Cheon GJ, Oh SY, Kim DS, et al. Implication of lymph node metastasis detected on 18F-FDG PET/CT for surgical planning in patients with peripheral intrahepatic cholangiocarcinoma. Clin Nucl Med. 2014;39:1–7.CrossRefPubMed

24.

Kim YJ, Yun M, Lee WJ, Kim KS, Lee JD. Usefulness of 18F-FDG PET in intrahepatic cholangiocarcinoma. Eur J Nucl Med Mol Imaging. 2003;30:1467–72.CrossRefPubMed

25.

Jo I, Won KS, Kim SH, Song B-I, Kang YN, Kim JY. Catheter Tract Implantation Metastasis Diagnosed by F-18 FDG PET/CT After Percutaneous Transhepatic Biliary Drainage for Hilar Cholangiocarcinoma. Nucl Med Mol Imaging. 2014;48:326–7.CrossRefPubMedPubMedCentral

26.

Kato T, Tsukamoto E, Kuge Y, Katoh C, Nambu T, Nobuta A, et al. Clinical role of (18)F-FDG PET for initial staging of patients with extrahepatic bile duct cancer. Eur J Nucl Med Mol Imaging. 2002;29:1047–54.CrossRefPubMed

27.

Fritscher-Ravens A, Bohuslavizki KH, Broering DC, Jenicke L, Schafer H, Buchert R, et al. FDG PET in the diagnosis of hilar cholangiocarcinoma. Nucl Med Commun. 2001;22:1277–85.CrossRefPubMed

28.

Petrowsky H, Wildbrett P, Husarik DB, Hany TF, Tam S, Jochum W, et al. Impact of integrated positron emission tomography and computed tomography on staging and management of gallbladder cancer and cholangiocarcinoma. J Hepatol. 2006;45:43–50.CrossRefPubMed

29.

Kawarada Y, Yamagiwa K, Das BC. Analysis of the relationships between clinicopathologic factors and survival time in intrahepatic cholangiocarcinoma. Am J Surg. 2002;183:679–85.CrossRefPubMed

30.

Li SQ, Liang LJ, Hua YP, Peng BG, He Q, Lu MD et al. Long-term outcome and prognostic factors of intrahepatic cholangiocarcinoma. Chin Med J (Engl). 2009;122:2286-91.

31.

Kitamura K, Hatano E, Higashi T, Seo S, Nakamoto Y, Narita M, et al. Prognostic value of (18)F-fluorodeoxyglucose positron emission tomography in patients with extrahepatic bile duct cancer. J Hepatobiliary Pancreat Sci. 2011;18:39–46.CrossRefPubMed

32.

Cho KM, Oh DY, Kim TY, Lee KH, Han SW, Im SA, et al. Metabolic Characteristics of Advanced Biliary Tract Cancer Using F-18-Fluorodeoxyglucose Positron Emission Tomography and Their Clinical Implications. Oncologist. 2015;20:926–33.CrossRefPubMedPubMedCentral

33.

Min M, Lin P, Lee MT, Shon IH, Lin M, Forstner D et al. Prognostic role of metabolic parameters of F-FDG PET-CT scan performed during radiation therapy in locally advanced head and neck squamous cell carcinoma. Eur J Nucl Med Mol Imaging. 2015; doi: 10.1007/s00259-015-3104-8.

34.

Park SB, Choi JY, Moon SH, Yoo J, Kim H, Ahn YC, et al. Prognostic value of volumetric metabolic parameters measured by [18F]fluorodeoxyglucose-positron emission tomography/computed tomography in patients with small cell lung cancer. Cancer Imaging. 2014;14:2.PubMedPubMedCentral

Title: The Role of F-18 FDG PET/CT in Intrahepatic Cholangiocarcinoma
Authors: Yeongjoo Lee
Ie Ryung Yoo
Sun Ha Boo
Hyoungwoo Kim
Hye Lim Park
Joo Hyun O
Publication date: 01-03-2017
Publisher: Springer Berlin Heidelberg
Published in: Nuclear Medicine and Molecular Imaging / Issue 1/2017
Print ISSN: 1869-3474
Electronic ISSN: 1869-3482
DOI: https://doi.org/10.1007/s13139-016-0440-y

At a glance: The STEP trials

Springer Medicine

The Role of F-18 FDG PET/CT in Intrahepatic Cholangiocarcinoma

Abstract

Purpose

Methods

Results

Conclusion

At a glance: The STEP trials

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2017

Scintigraphic Evidence for Overdiagnosis of Small PE on CT Pulmonary Angiography

Usefulness of SPECT/CT in Parathyroid Lesion Detection in Patients with Thyroid Parenchymal 99mTc-Sestamibi Retention

FDG-PET Identification of Infected Pulmonary Artery Conduit Following Tetralogy of Fallot (TOF) Repair

Risk Stratification for Avascular Necrosis of the Femoral Head After Internal Fixation of Femoral Neck Fractures by Post-Operative Bone SPECT/CT

Unusual Horner’s Syndrome in Recurrent Breast Cancer: Evaluation Using 18F-FDG PET/CT

Correlation of Molecular Subtypes of Invasive Ductal Carcinoma of Breast with Glucose Metabolism in FDG PET/CT: Based on the Recommendations of the St. Gallen Consensus Meeting 2013